CancerNetwork Members: Login | Register
Become a fan on  Facebook  Add us on  Google Plus Follow us on  Twitter Join us on LinkedIn Sign up for our Newsletters Subscribe to our RSS Feed

 

CancerNetwork SearchMedica Medline Drugs

Powered by SearchMedica

 
PUBLICATIONS
NEWS
PODCASTS
TOPICS
BLOGS
NURSES
PATIENTS
JOBS
CONFERENCES
CME
SUPPLEMENTS
 

Home »

ONCOLOGY. Vol. 10 No. 2
 

Surgeon Questions Routine Use of Preoperative TPN in Cancer Patients

February 1, 1996

Cancer cachexia may be an immunologic phenomenon related to increased cytokine production that occurs in response to the tumor itself or to the stress of surgery, John M. Daly, MD, said at the Society of Surgical Oncology's Annual Cancer Symposium. As such, the routine administration of preoperative total parenteral nutrition (TPN) may not be a useful strategy for all types of cancer.

It is unlikely that cancer cachexia is due to a nutritional deficit alone, since administration of proper nutrition does not, by itself, abrogate the symptoms, said Dr. Daly, Lewis Arterbury Stimson Professor and Chairman, Department of Surgery, Cornell University Medical College, and Surgeon-in-Chief, The New York Hospital.

Additionally, malnutrition causes immunologic changes that resemble those in a cachectic cancer patient, Dr. Daly said in the Society's John Wayne Clinical Research Lecture. For example, a decreased and abnormal in vitro cellular response of many immune cells, such as neutrophils, natural killer (NK) cells, and lymphocytes, can be observed in both malnourished patients and those with cancer cachexia.

Monoclonal antibodies to immunologic cytokines such as tumor necrosis factor (TNF) or gamma-interferon have been shown to improve cachetic symptoms in animal experiments, thus providing support for an immunologic role in cancer-induced malnutrition, he said.

Dr. Daly questioned the routine use of preoperative TPN in the cancer patient, because of its cost, lack of established efficacy, and associated minor infectious

the routine use of preoperative TPN in the cancer patient, because of its cost, lack of established efficacy, and associated minor infectious complications. He suspects that these complications may result from the immunologic effects of TPN, which has been shown to decrease immune function in rats, down-regulating macrophage and splenocyte cell function.

Benefits of Supplemented TPN

However, when TPN is supplemented with certain amino acids, such as glutamine dipeptide, a clear benefit has been shown in bone marrow transplant patients in terms of decreased infections and shorter hospital stays, Dr. Daly said.

These supplements may serve as a form of "immuno-nutrition," acting on the body to increase the immune response, thus decreasing infections and improving wound healing, he said. The amino acid arginine, for example, has been shown to increase T-lymphocyte, macrophage, and NK cell activation; cytokine production; and the delayed-type hypersensitivity response.

Dr. Daly said that adding amino acids or certain fatty acids to TPN may give patients a better postoperative outcome. For example, esophageal carcinoma patients undergoing esophagectomy were improved postoperatively when given enteral nutrition supplemented with arginine and omega 3-fatty acids (eicosapentanoic acid).

Such evidence suggests a model in which cancer-related malnutrition leads to immune suppression that could result in infection and metastases.

Supplemented enteral nutrition may have a role in improving the immune response under such conditions, Dr. Daly said. However, for many cancers, preoperative TPN does not seem to be indicated, considering the risk of complications. He believes that its routine use should be avoided, and preoperative supplemented TPN should be used only in patients with severe malnutrition or in those undergoing bone marrow transplantation.

 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.






 
TOPIC INDEX

Cancer Types

 
  • Breast
  • Breast (HER2+)
  • Breast (Triple-Negative)
  • CML
  • Colorectal
  • Gastrointestinal
  • GIST
  • Genitourinary
  • Gynecologic
  • Head & Neck
  • Hematology
  • Kidney (Renal Cell)
  • Leukemia
  • Lung
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Ovarian
  • Prostate
  • Sarcoma

Supportive Care

More Topics

  • Bone Metastases
  • End-of-Life Care
  • Palliative Care
  • Ethics in Oncology
  • Practice Management
  • Practice & Policy


All Topics 


 
IMAGE IQ

Lower Back Pain in an Elderly Man With a History of Localized Prostate Cancer
James B. Yu, MD1 , May 17, 2013

A 70-year-old man with a history of localized prostate cancer treated with whole-pelvis radiation therapy with a boost to the prostate, in conjunction with androgen deprivation therapy 7 years prior, presented with lower back pain. A bone scan revealed an area of activity in the sacrum. What is the most likely diagnosis?

More Image IQs 

 
FROM PHYSICIANS PRACTICE
Primary Care Can't Thrive Without Nurse Practitioners
Courtney H. Lyder, ND,  May 17, 2013
With a projected shortfall of primary-care physicians, it's time for alternate solutions to patient care. Nurse practitioners are one logical remedy.
VWhat Physicians Can Learn from the Allscripts EHR Lawsuit
Marisa Torrieri,  May 16, 2013
Lawsuit prompts question: What should physicians do to ensure they end up with a great EHR instead of buyer’s remorse?
Eight Ways ICD-9 Will Still Matter to Medical Practices
Brenda Edwards, CPC,  May 15, 2013
What should your medical practice do with your ICD-9-CM book after October 1, 2014? Keep it.
Seven Ways Technology Can Speed Up Patient Collections
Cheyenne Brinson,  May 15, 2013
Failing to adopt widely available billing and collections technology can cost medical practices big. Here's how to do it right.
Four Reasons Private Medical Practice is Becoming Extinct
Carol Stryker,  May 15, 2013
It’s becoming increasingly difficult for private medical practices to thrive. Here’s what’s driving the trend toward consolidation.
 

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Colorectal Lesions
  • “This Is My Last Day on Earth”
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Skin Lesions
  • Slide Show: Squamous Cell Carcinoma of the Head and Neck
  • “This Is My Last Day on Earth”
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Recurrent Epithelial Ovarian Cancer: An Update on Treatment
  • Colorectal Lesions
  • ONS: Understanding Spirituality and How It Can Be Used to Help Patients
  • New AUA Guidelines for Prostate Cancer Screening
  • 50 Shades of Pink—And Why It Helps to Know the Difference
  • Genomics Studies Identify Testicular Cancer Risk Variants
  • Lower Back Pain in an Elderly Man With a History of Localized Prostate Cancer
  • FDA Approves Erlotinib (Tarceva) as First-Line Lung Cancer Therapy for Certain Patients
Click here to subscribe to our newsletter
 
COMMENTS
  • Most Commented
  • Most Recent
  • “This Is My Last Day on Earth”
  • Financial Toxicity, Part II: How Can We Help With the Burden of Treatment-Related Costs?
  • Patient Quality of Life Endpoints in Oncology Trials, Part II
  • Who's Coding Whom?
  • “How Do I Say This Nicely? Your Oncologist Wasn't Following Guidelines”
  • Cancer Metabolism as a Therapeutic Target
  • Study: Cholesterol Drugs Reduced Risk of Prostate Cancer Death
  • “This Is My Last Day on Earth”
  • ONS: Safe Handling of Chemotherapy
  • Financial Toxicity, Part II: How Can We Help With the Burden of Treatment-Related Costs?
Click here to subscribe to our newsletter



CancerNetwork on Facebook

CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy